Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Open access
2,480
Views
0
CrossRef citations to date
0
Altmetric
Oncology
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
Matthew Matasara Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USACorrespondence[email protected]
View further author information
, View further author information
Anthony Masaquelb Genentech, Inc, South San Francisco, CA, USAView further author information
, Rodrigo S. Hoc F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Aino Launonenc F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
, Carmen D. Ngb Genentech, Inc, South San Francisco, CA, USAView further author information
, Rongrong Wangb Genentech, Inc, South San Francisco, CA, USAView further author information
, David Foxb Genentech, Inc, South San Francisco, CA, USAView further author information
, Farah Hossainb Genentech, Inc, South San Francisco, CA, USAView further author information
, Jia Lib Genentech, Inc, South San Francisco, CA, USAView further author information
& John M. Burked Rocky Mountain Cancer Centers/US Oncology, Aurora, CO, USAView further author information
show all
Pages 1134-1144
|
Received 07 Jul 2023, Accepted 30 Aug 2023, Published online: 15 Sep 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.